{
    "organizations": [],
    "uuid": "a9fd751ab9751d9c9684a2db76c7ad6bb32ba152",
    "author": "",
    "url": "https://www.reuters.com/article/brief-helix-biopharma-signs-binding-lett/brief-helix-biopharma-signs-binding-letter-of-intent-for-development-of-new-car-t-technologies-idUSFWN1OZ0YY",
    "ord_in_thread": 0,
    "title": "BRIEF-Helix Biopharma Signs Binding Letter Of Intent For Development Of New Car-T Technologies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 4, 2018 / 10:55 PM / Updated 7 minutes ago BRIEF-Helix Biopharma Signs Binding Letter Of Intent For Development Of New Car-T Technologies Reuters Staff \nJan 4 (Reuters) - Helix Biopharma Corp: \n* HELIX BIOPHARMA CORP. SIGNS BINDING LETTER OF INTENT FOR DEVELOPMENT OF NEW CAR-T TECHNOLOGIES \n* SAYS‍ IMMEDIATE FOCUS WILL INVOLVE PRECLINICAL WORK IN SUPPORT OF A NEW IND APPLICATION OF A CAR-T FOR HEMATOLOGICAL MALIGNANCIES​ \n* SAYS ‍FINALIZATION OF COLLABORATIVE BINDING LOI WITH PROMAB BIOTECHNOLOGIES TO DEVELOP CHIMERIC ANTIGEN RECEPTOR CAR-T FOR HEMATOLOGICAL MALIGNANCES AND SOLID TUMOURS​ \n* SAYS UNDER AGREEMENT,CO RETAINS EXCLUSIVE LICENSE FOR COMMERCIALIZATION OF PRODUCT CANDIDATES DEVELOPED ALONE OR IN COMBINATION WITH DOS47​ Source text for Eikon: Further company coverage:",
    "published": "2018-01-05T00:54:00.000+02:00",
    "crawled": "2018-01-05T01:11:51.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "biopharma",
        "sign",
        "binding",
        "letter",
        "intent",
        "development",
        "new",
        "technology",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "helix",
        "biopharma",
        "corp",
        "helix",
        "biopharma",
        "sign",
        "binding",
        "letter",
        "intent",
        "development",
        "new",
        "technology",
        "immediate",
        "focus",
        "involve",
        "preclinical",
        "work",
        "support",
        "new",
        "ind",
        "application",
        "hematological",
        "say",
        "collaborative",
        "binding",
        "loi",
        "promab",
        "biotechnology",
        "develop",
        "chimeric",
        "antigen",
        "receptor",
        "hematological",
        "malignance",
        "solid",
        "say",
        "agreement",
        "co",
        "retains",
        "exclusive",
        "license",
        "commercialization",
        "product",
        "candidate",
        "developed",
        "alone",
        "combination",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}